Purpose: RRx-001, a minimally toxic tumor-associated macrophage and neutrophil-repolarizing agent, is under investigation in Phase II clinical trials as a sensitizer/resensitizer to cisplatin and carboplatin. On the basis of anecdotal clinical observations of improved platinum tolerability following a priming period with RRx-001 as well as preclinical studies that have previously demonstrated radioprotection of intestinal stem cells and cardioprotection from doxorubicin, the in vivo cytoprotective potential of RRx-001 pretreatment against cisplatin-induced bone marrow suppression and renal toxicity was investigated.
Methods: BALB/c mice were divided into three groups: (1) no treatment, (2) vehicle and cisplatin only, and (3) RRx-001 and cisplatin. RRx-001 treatment (5 mg/kg every other day for 3 days) was initiated 3 days prior to cisplatin administration. Blood was collected from the femoral vein at different intervals to measure total hemoglobin and leukocyte counts as well as renal functional markers (serum urea, creatinine and creatinine clearance). Metaphase spreads were prepared from whole bone marrow cells as markers of clastogenicity.
Results: RRx-001 pretreatment significantly decreased (P < 0.05) the blood urea nitrogen and creatinine levels. A statistically significant (P < 0.05) reduction in the mean total chromosome aberration frequency per metaphase in the RRx-001 and cisplatin group compared to the cisplatin-only group was observed.
Conclusions: This study is the first to demonstrate that RRx-001 has nephro-, geno- and myeloprotective effects in vivo. Importantly, RRx-001 did not protect sarcoma-180 solid tumor xenografts against cisplatin-induced cytotoxicity. These results potentially support the use of RRx-001 as a chemoprotector against cisplatin-induced toxicities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00432-017-2416-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RRx-001 Exerts Neuroprotection Against LPS-Induced Microglia Activation and Neuroinflammation Through Disturbing the TLR4 Pathway.
Front Pharmacol
April 2022
Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
Article Synopsis
- Neuroinflammation is linked to various central nervous system diseases, and the study examined the anti-cancer compound RRx-001's effect on this process.
- RRx-001 significantly reduced the release of pro-inflammatory cytokines and inhibited pathways like NF-κB and MAPK that are activated by LPS, a substance that triggers inflammation.
- In a mouse model, RRx-001 decreased microglial activation and neuron loss caused by neuroinflammation, suggesting its potential as a treatment for brain diseases related to inflammation.
RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.
Front Pharmacol
April 2021
Scientific Research Department, Armed Forces Radiobiology Research Institute, Uniformed Services University, Bethesda, MD, United States.
The present studies evaluate the prophylactic radioprotective effects of 1-bromoacetyl-3, 3-dinitroazetidine (RRx-001), a phase III anticancer agent that inhibits c-myc and downregulates CD-47, after total body irradiation (TBI), in lethally and sublethally irradiated CD2F1 male mice. A single dose of RRx-001 was administered by intraperitoneal (IP) injection 24 h prior to a lethal or sublethal radiation dose. When irradiated with 9.
View Article and Find Full Text PDFCardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Mol Pharm
July 2019
Department of Bioengineering , University of California San Diego, 9500 Gilman Drive , La Jolla , California 92093 , United States.
Anthracycline chemotherapy (e.g., doxorubicin or DOX) is associated with a cumulative dose-dependent cardiac dysfunction that may lead to congestive heart failure, which limits both its use and usefulness in the clinic.
View Article and Find Full Text PDFArticle Synopsis
- A patient with advanced neuroendocrine prostate cancer received multiple previous treatments before being part of a Phase II clinical trial.
- The patient was treated with RRx-001, a dual inhibitor targeting CD-47 and SIRP-α.
- After undergoing platinum-based chemotherapy, the patient achieved a complete metabolic response, indicating significant improvement in their condition.
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.
J Investig Med High Impact Case Rep
March 2018
Baptist Health, Lexington, KY, USA.
This case report describes the clinical course of a heavily pretreated patient enrolled on the Phase II QUADRUPLE THREAT clinical trial (NCT02489903) with recurrent metastatic epithelial ovarian cancer that was previously treated with a platinum doublet and that benefited from another reintroduction of a platinum doublet after a brief priming period with RRx-001. Platinum-taxane combination is the initial treatment of choice in ovarian cancer and the "go-to regimen" for patients with recurrent, platinum-sensitive disease. However, platinum resistance is an inevitable and uniformly fatal development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!